Patient safety is a top priority for Novo Nordisk, and we take all reports about adverse events from the use of our medicines very seriously, the spokesperson said.
It analyzes pathway-level variants (GLP1R (rs6923761), and FTO (rs9939609)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction
Right now, Semaglutide is still on the FDA shortage list, allowing compounding pharmacies to create versions to meet the demand
The lipid benefits appear to be secondary effects related to weight loss, improved insulin sensitivity, and direct metabolic actions of the dual incretin pathway
But once you get there, the next step is just as important: maintaining your results
Source : NEJM SURMOUNT-1 Trial Double the impact on A1C GLP-1 + GIP therapy dropped A1C by up to 2.3 percentage points, compared to just 1.86 with GLP-1 1mg